Sign Up Now!

Sign up and get personalized intelligence briefing delivered daily.


Sign Up

Articles related to "industry"


State of DevOps Report Finds Maturity Varies Widely by Industry

  • Alanna Brown, senior director of community and developer relations at Puppet, told ITPro Today that the State of DevOps: Industry Report Card slices Puppet's 2019 survey data by industry and grades each industry based on their DevOps practices and security integration.
  • The scorecard gave the technology industry an "A" for DevOps adoption and an "A-" for security integration as part of the DevOps development pipeline.
  • Brown noted that it was expected that companies in the technology industry would be leading the pack in terms of security integration because DevOps tends to be part of the DNA of those organizations.
  • In contrast, the financial services and insurance industry scored only a "B" for DevOps and a "C-" for security integration.
  • One of the surprises for Brown in the report was that government didn't score well for DevOps adoption, only getting a "C" grade.

save | comments | report | share on


The war on food waste is a waste of time

  • As Walmart works “to reduce food waste from farm to fork,” it underpays its employees and, according to some, has leveraged its anti-competitive market power to support industrialized, resource-intensive kinds of agriculture that pose environmental harms much greater than any food waste reduction efforts could make up for.
  • And while corporate funding isn’t so far away — such centers host conferences with food industry scions and interest groups — the uptake of a problem whose solutions almost exclusively benefit corporate actors, incidentally or intentionally, is evidence of influence enough.
  • (A bar chart wondering if the global fossil fuels industry were a country would make even less sense, as those emissions are magnitudes of scale more than China’s.) Vox published a video calling food waste the world’s “dumbest problem,” not because of its lamentable narrowness, but because it is so

save | comments | report | share on


What Happens If I Don't Fill Out My Census Form? (2019)

  • Originally, the census was meant to be a way to count everyone so that the members of the House of Representatives could be allocated properly to the states.
  • Every 10 years there would be a count, and states with more people got more members in the House.
  • If your response has not been received -- or if you didn't complete all the questions on your form -- someone from the census will contact you for that information.
  • However, even if you don't get fined for not filling out the census form, there are some good reasons you should do it anyway.
  • Seats in the House of Representatives seats are apportioned by population, with the most populous states receiving the most seats.
  • So, not filling out the census form may cost you something in the long run.

save | comments | report | share on


Why it was inevitable that Bombardier’s shot at the sky brought the Canadian giant down

  • The company’s audacious attempt to move into the high stakes world of passenger jets left it with crippling debt and forced a fire sale of assets that this week culminated in the decision to sell its US$8 billion-a-year train manufacturing business to Alstom of France.
  • Yet, while Bombardier defined it as a regional jet — a market not addressed by Boeing or Airbus — it was obvious that the CSeries could eventually be used more efficiently over a long enough range to start challenging the incumbents’ smallest aircraft.
  • Just as it appeared most of the program risk had been overcome — and after Bombardier had absorbed billions in extra costs, along with repeated public bailouts — it was forced to sell control of the CSeries to Airbus for the paltry sum of $1 in 2017.

save | comments | report | share on


Moody's lowers its forecast for global auto sales in 2020 due to the coronavirus, anticipating lower demand and supply disruptions

  • FRANKFURT, Germany (AP) — Ratings agency Moody's is lowering its forecast for global auto sales because of the new coronavirus outbreak.
  • It now reckons that sales will decline 2.5% decline in 2020 instead of only 0.9%.
  • This year's anticipated decline follows a fall in 2019 of 4.6%.
  • Moody's said in a report Wednesday that the outbreak would reduce demand and disrupt supplies of parts and raw materials for the auto industry.
  • Moody's said new limits on carbon dioxide emissions in Europe would also weigh on the auto industry there.
  • Automakers must invest heavily in new electric autos that have zero local emissions even as profits from sales of conventional cars weakens in key markets.

save | comments | report | share on


Coronavirus vaccine: Moderna looks to ramp up production - Business Insider

  • A small, buzzy biotech is leading the race to develop a vaccine against the coronavirus, outpacing some of the world's largest pharmaceutical companies like Johnson & Johnson and Sanofi in the process.
  • Leaders of the US health agency said they plan to start testing Moderna's potential vaccine in humans by April.
  • Moderna, like most early-stage biotechs, doesn't have commercial products or the ability to manufacture a drug or vaccine in large quantities.
  • Read more: A buzzy biotech just outpaced the drug industry's giants to ship the first potential coronavirus vaccine.
  • A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak, which is causing the disease called COVID-19.
  • The first clinical trial of Moderna's drug will test three doses of the vaccine in health adults, studying to see if the vaccine is safe and creates an immune response.

save | comments | report | share on


Coronavirus vaccine: Moderna looks to ramp up production - Business Insider

  • A small, buzzy biotech is leading the race to develop a vaccine against the coronavirus, outpacing some of the world's largest pharmaceutical companies like Johnson & Johnson and Sanofi in the process.
  • Leaders of the US health agency said they plan to start testing Moderna's potential vaccine in humans by April.
  • Moderna, like most early-stage biotechs, doesn't have commercial products or the ability to manufacture a drug or vaccine in large quantities.
  • Read more: A buzzy biotech just outpaced the drug industry's giants to ship the first potential coronavirus vaccine.
  • A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak, which is causing the disease called COVID-19.
  • The first clinical trial of Moderna's drug will test three doses of the vaccine in health adults, studying to see if the vaccine is safe and creates an immune response.

save | comments | report | share on


Buzzy biotech Moderna is 'looking at all options' to ramp up production just days after shipping the first potential coronavirus vaccine

  • A small, buzzy biotech is leading the race to develop a vaccine against the coronavirus, outpacing some of the world's largest pharmaceutical companies like Johnson & Johnson and Sanofi in the process.
  • Leaders of the US health agency said they plan to start testing Moderna's potential vaccine in humans by April.
  • Moderna, like most early-stage biotechs, doesn't have commercial products or the ability to manufacture a drug or vaccine in large quantities.
  • Read more: A buzzy biotech just outpaced the drug industry's giants to ship the first potential coronavirus vaccine.
  • A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak, which is causing the disease called COVID-19.
  • The first clinical trial of Moderna's drug will test three doses of the vaccine in health adults, studying to see if the vaccine is safe and creates an immune response.

save | comments | report | share on


Field Trip raised $8.5 million to take psychedelic medicine mainstream. We got an exclusive look at the pitch deck that helped make it happen.

  • There's a wave of startups working on developing FDA-approved drugs from compounds like psilocybin, one of the chief active ingredients in magic mushrooms, and various compounds in ibogaine, a naturally occurring hallucinogen, among others.
  • To that end, Toronto-based Field Trip Psychedelics recently closed an $8.5 million Series A funding round to build out a series of clinics for psychedelic therapies, first in Toronto, New York, and Los Angeles.
  • The clinics will add other treatments as research moves forward, and Levy said he hopes some of that research will be conducted at Field Trip's facility in Jamaica.
  • Levy said the fundraising process took a little under four months to close, relatively quick for a Series A round in an emerging industry.
  • Levy said what attracted investors to Field Trip is that the company is not focused exclusively on drug development and the "binary outcomes" that come with that process.

save | comments | report | share on


Field Trip Psychedelics $8.5 million Series A pitch deck - Business Insider

  • There's a wave of startups working on developing FDA-approved drugs from compounds like psilocybin, one of the chief active ingredients in magic mushrooms, and various compounds in ibogaine, a naturally occurring hallucinogen, among others.
  • To that end, Toronto-based Field Trip Psychedelics recently closed an $8.5 million Series A funding round to build out a series of clinics for psychedelic therapies, first in Toronto, New York, and Los Angeles.
  • The clinics will add other treatments as research moves forward, and Levy said he hopes some of that research will be conducted at Field Trip's facility in Jamaica.
  • Levy said the fundraising process took a little under four months to close, relatively quick for a Series A round in an emerging industry.
  • Levy said what attracted investors to Field Trip is that the company is not focused exclusively on drug development and the "binary outcomes" that come with that process.

save | comments | report | share on